FDA Purple Book · Reference family
reslizumab (Cinqair)
reslizumab is an FDA-licensed reference biologic from Teva Respiratory, LLC. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2016
Reference approved
Reference product
351(a)BLA 761033
Cinqair reslizumab
Teva Respiratory, LLC
- Approved
- Mar 23, 2016
- Marketing
- Rx
- Center
- CDER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for reslizumab, in chronological order.
Reference approval
Approval date of the reference reslizumab product.
10 yr 4 mo ago
Frequently asked questions
Are there biosimilars approved for reslizumab (Cinqair)?
No 351(k) biosimilars or interchangeable biosimilars referencing reslizumab are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.